SB-480848 (Glaxosmithkline)
Document Type
Article
Publication Date
3-1-2004
Abstract
SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.
Montclair State University Digital Commons Citation
Rotella, David, "SB-480848 (Glaxosmithkline)" (2004). Department of Chemistry and Biochemistry Faculty Scholarship and Creative Works. 266.
https://digitalcommons.montclair.edu/chem-biochem-facpubs/266
COinS